Prospectus Supplement
(To Prospectus dated November 6, 2020)
9,600,000 Shares

Common Stock
We are offering 9,600,000 shares of our common stock, $0.01 par value per share. In addition, we expect to enter into a forward sale agreement with each of BofA Securities, Inc. and J.P. Morgan Securities LLC (or affiliates thereof), which we refer to in this capacity as the forward purchasers. In connection with the forward sale agreements, we expect that the forward purchasers or their affiliates will borrow from third parties and sell to the underwriters an aggregate of 6,500,000 shares of our common stock, $0.01 par value per share, that will be delivered in this offering.
We will receive proceeds from the sale of 3,100,000 shares of our common stock offered by us in this offering, but we will not initially receive any proceeds from the sale of 6,500,000 shares of our common stock offered by the forward purchasers or their affiliates. We expect to physically settle the forward sale agreements (by the delivery of shares of our common stock) and receive proceeds from the sale of those shares of our common stock upon one or more forward settlement dates no later than 18 months from the date hereof. We may also elect to cash settle or net share settle all or a portion of our obligations under a forward sale agreement (if we conclude that it is in our best interest to do so). If we elect to cash settle a forward sale agreement, we may not receive any proceeds, and we may owe cash to the relevant forward purchaser in certain circumstances. If we elect to net share settle a forward sale agreement, we will not receive any proceeds, and we may owe shares of our common stock to the relevant forward purchaser in certain circumstances. See “Underwriting—Forward Sale Agreements.”
If any forward purchaser or its affiliate does not deliver and sell all of the shares of our common stock to be delivered and sold by it pursuant to the terms of the underwriting agreement, we will issue and sell directly to the underwriters the number of shares of our common stock not delivered and sold by such forward purchaser or its affiliate, and under such circumstances the number of shares of our common stock underlying the relevant forward sale agreement will be decreased by the number of shares of our common stock that we issue and sell.
We are organized and conduct our operations to qualify as a real estate investment trust, or REIT, for federal income tax purposes. To assist us in complying with certain federal income tax requirements applicable to REITs, our charter contains certain restrictions relating to the ownership and transfer of our capital stock, including an ownership limit of 9.8% of the outstanding shares of our common stock.
Our common stock is listed on the New York Stock Exchange, or NYSE, under the symbol “REXR,” and the last reported sale price of our common stock on the NYSE on September 21, 2021 was $60.12 per share.
Investing in our common stock involves risks. See “Risk Factors” beginning on page S-7 of this prospectus supplement and the risks set forth under the caption “Item 1A. Risk Factors” included in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which is incorporated by reference herein, for certain risks relevant to an investment in our common stock.
The underwriters have agreed to purchase the shares of our common stock at a price of $58.65 per share. As a result, we will receive approximately $181.8 million of net proceeds from the 3,100,000 shares that we issue and sell in this offering and approximately $381.2 million upon full physical settlement of the forward sale agreements at an initial forward sale price of $58.65 per share, subject to certain adjustments pursuant to such forward sale agreements, in each case before expenses from this offering. The shares may be offered by the underwriters from time to time to purchasers directly or through agents, or through brokers in brokerage transactions on the NYSE, or to dealers in negotiated transactions or in a combination of such methods of sale, at a fixed price or prices, which may be changed, or at market prices prevailing at the time of sale, at prices related to such prevailing market prices or at negotiated prices. See “Underwriting” for a description of the compensation payable to the underwriters.
The underwriters have been granted an option, exercisable in whole or in part from time to time, to purchase up to an additional 1,440,000 shares of our common stock at the purchase price described above, within 30 days from the date of this prospectus supplement. Upon any exercise of such option, we expect to enter into an additional forward sale agreement with each of the forward purchasers (on substantially the same terms as the initial forward sale agreements) in respect of the number of shares sold by the applicable forward purchaser or its affiliate in connection with the exercise of such option. Unless the context requires otherwise, the term “forward sale agreement” as used in this prospectus supplement includes any additional forward sale agreement that we enter into in connection with the exercise by the underwriters of their option to purchase additional shares. In such event, if any forward purchaser or its affiliate does not deliver and sell all of the shares of our common stock to be delivered and sold by it in connection with the exercise of such option, we will issue and sell directly to the underwriters the number of shares of our common stock not delivered and sold by the forward purchaser or its affiliate, and under such circumstances the number of shares of our common stock underlying the additional forward sale agreement will be decreased by the number of shares of our common stock that we issue and sell.
Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement and the accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.
The underwriters expect to deliver the shares to purchasers on or about September 27, 2021 through the book-entry facilities of The Depository Trust Company.
Joint Book-Running Managers
| | |
BofA Securities | | J.P. Morgan |
The date of this prospectus supplement is September 22, 2021